[Media Releases] AstraZeneca, LegoChem Biosciences To Co-Develop Novel Antibiotics (Firstword Pharma, 23 Dec 2012)
Title: AstraZeneca, LegoChem Biosciences To Co-Develop Novel Antibiotics Publication: Firstword Pharma Date: 23 Dec 2012 URL: link to website
· AstraZeneca licensed an antibiotic drug candidate from South Korea's LegoChem Biosciences to treat drug-resistant bacterial infections, reported Asian Scientist. · The companies will investigate whether the combination of a cephalosporin with AstraZeneca's preclinical beta lactamase inhibitor (BLI) can break down Gram-negative bacteria's resistance to the treatment.
About LegoChem Biosciences LegoChem Biosciences, Inc. (LCB) is a research-based biotechnology company dedicated to discovering, developing, and commercializing innovative medicines by leveraging our chemistry expertise to make conventional biologics targeted and more potent for the benefit of patients with diseases of high unmet medical needs. We are advancing sustainable pipelines in therapeutic areas in antibiotics, anti-coagulants, oncology, antibody-drug conjugate (ADC), and protein-drug conjugate (PDC). |